Fig. 1 · Structure

Documents & Downloads

FK866

Cat. No. A11279 CAS 658084-64-1

NMPRTase Inhibitor

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

In Stock

Publications for FK866

7 publications citing this product

  1. Natsuko Kitajima, .et al. , J Cell Mol Med, 2026, May 20;30(10):e71187 PMID: 42159653
  2. T Nakajo, .et al. , Biochem Biophys Res Commun, 2024, Oct 30:731:150371 PMID: 39004065
  3. Takeshi Katayoshi, .et al. , Sci Rep, 2022, Nov 9;12(1):19040 PMID: 36352014
  4. Takeshi Nakamura, .et al. , Shimane Journal of Medical Science, 2022, 38 (2), 59-66
  5. Takeshi Katayoshi, .et al. , J Photochem Photobiol B, 2021, Jun 12;221:112238 PMID: 34130091
  6. Yool Lee, .et al. , Sci Adv, 2021, 7 PMID: 33579708
  7. Peter M LoCoco, .et al. , eLife, 2017, 6: e29626 PMID: 29125463

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

FK866 inhibits human nicotinamide phosphoribosyltransferase (NAMPT). In a purified-enzyme study, its reported inhibition constants depended on ATP coupling and the substrate used for kinetic analysis; these biochemical Ki values should be interpreted in their assay context. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
NMPRTase (Cell-free assay) 0.09 nM

Cellular Effect

Cell Line Activity Value Description Reference
A2780 IC50 0.001 μM Inhibition of NAMPT in human A2780 cells assessed as decrease in cell viability after 72 hrs by SRB assay [PMID: 27541271]
A2780 IC50 0.001 μM Cytotoxicity against human A2780 cells after 72 hrs by SRB assay [PMID: 23617784]
A2780 IC50 0.001 μM Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay [PMID: 24405419]
A2780 IC50 0.001 μM Antiproliferative activity against human A2780 cells assessed as growth inhibition after 72 hrs by SRB-based microplate reader analysis [PMID: 23859118]
A2780 IC50 1.6 nM Cytotoxicity against human A2780 cells assessed as growth inhibition after 72 hrs by WST-1 assay [PMID: 24164086]
A2780 IC50 5.7 nM Cytotoxicity against human A2780 cells by clonogenic assay [PMID: 24164086]
A-431 IC50 6.1 nM Cytotoxicity against human A431 cells by clonogenic assay [PMID: 24164086]
A549 IC50 < 0.16 μM Cytotoxicity against human A549 cells after 6 days by SRB assay [PMID: 21330015]
A549 IC50 0.028 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by cell titer glo luminescent assay [PMID: 35640078]
A549 IC50 3.7 μM Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay [PMID: 29348808]
DU-145 IC50 5.12 nM Antiproliferative activity against human DU145 cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay [PMID: 30992165]
HCT-116 IC50 < 0.16 μM Cytotoxicity against human HCT116 cells after 6 days by SRB assay [PMID: 21330015]
HCT-116 IC50 1.6 μM Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT assay [PMID: 29348808]
HCT-116 IC50 1.6 μM Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 28885834]
HCT-116 IC50 10.9 nM Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay [PMID: 24164086]
HCT-116 IC50 946 nM Cytotoxicity against APO866-resistant human HCT116 cells assessed as growth inhibition after 72 hrs by WST-1 assay [PMID: 24164086]
HeLa GI50 1.34 nM Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by CCK-8 assay [PMID: 27224875]
HeLa IC50 3.75 nM Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by CCK-8 assay [PMID: 30992165]
HepG2 IC50 0.89 μM Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay [PMID: 29348808]
HepG2 IC50 0.89 μM Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 28885834]

20 records · Scroll to view more

FK866 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of FK866 from 2 published references.

FK866 In Vitro Studies

In oxidatively stressed A1A1 rat neuronal cells, 10 nM FK866 blocked NAD/NADH recovery associated with P7C3-A20 or nicotinamide during a 60-minute recovery phase. This combined-treatment result supports use of FK866 as a pathway-blocking tool in this model. [2]

ATP-dependent FK866 inhibition constants for human NAMPT

Biochemical assay · Purified recombinant human NAMPT; cell-free NMN synthesis assay [1]

FK866 inhibited human NAMPT in both ATP-coupled and non-ATP-coupled assays. The reported constants depended on ATP coupling and the substrate used for the kinetic analysis; they are Ki values rather than cellular IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Non-ATP-coupled NMN synthesis, with respect to PRPPKi 730 ± 75 pM[1]
Non-ATP-coupled NMN synthesis, with respect to NAMKi 5000 ± 500 pM[1]
ATP-coupled NMN synthesis, with respect to PRPPKi 10 ± 1 pM[1]
ATP-coupled NMN synthesis, with respect to NAMKi 150 ± 18 pM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Inhibitor concentrations varied to cover 0–80% inhibition; exact FK866 concentration series not specified in the adopted method text.
Exposure duration
Three samples quenched at 15-minute intervals for initial-rate measurements.
Method
25°C, pH 7.5. ATP-coupled method: 200 μM PRPP, 100 nM radiolabeled NAM, 2.5 mM ATP, 5 mM MgCl2 and 2.2 nM enzyme in 50 mM HEPES, 50 mM NaCl and 1 mM THP. Without ATP: 100 μM PRPP, 1 μM radiolabeled NAM and 88 nM enzyme with the stated buffer components.
Co-treatment
ATP-present and ATP-absent assay conditions; other inhibitors in Table 2 are comparators, not co-treatments.
Reported limits
FK866 supplier, stock vehicle and explicit salt form not identified in read material text. Reported ± is not assigned SD or SEM.
Methods and source locations

Compound reported in the paper: FK866; Compound label in the paper: FK866

Compound-level research findings; no validation of A11279 purity, lot, salt equivalence or performance.

Table 2, FK866 row, PRPP/NAM columns with and without ATP; Experimental Procedures: NAMPT Inhibition and Analysis of Data; Results: Inhibition Studies

Non-ATP-coupled NMN synthesis, with respect to PRPP: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; Non-ATP-coupled NMN synthesis, with respect to PRPP

Non-ATP-coupled NMN synthesis, with respect to NAM: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; Non-ATP-coupled NMN synthesis, with respect to NAM

ATP-coupled NMN synthesis, with respect to PRPP: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; ATP-coupled NMN synthesis, with respect to PRPP

ATP-coupled NMN synthesis, with respect to NAM: Initial rates of radiolabeled NMN formation determined by HPLC and fitted using competitive-inhibition equations, with correction for inhibitor depletion. Experiments performed in duplicate. Reported ± retained; error type not defined in the adopted table/method text. Parenthetical numbers in the table are Km/Ki ratios, not sample sizes. — Table 2, FK866 row; ATP-coupled NMN synthesis, with respect to NAM

FK866 blocks NAD/NADH recovery in oxidatively stressed A1A1 cells

Cell-based study · Established A1A1 rat cortical neuronal cell line; hydrogen-peroxide-induced NAD/NADH depletion [2]

After oxidative pretreatment, FK866 co-treatment blocked the NAD/NADH recovery associated with P7C3-A20 or nicotinamide. The endpoint was combined NAD/NADH abundance, not an isolated NAD+ measurement or direct NAMPT enzyme activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular NAD/NADH recovery after oxidative depletionQualitative recovery response FK866 blocked recovery associated with P7C3-A20 or nicotinamide after H2O2 pretreatment; P7C3-A20 and nicotinamide did not significantly increase the basal signal without H2O2.[2]

Literature-Reported Treatment Conditions

Treatment concentration
FK866 10 nM.
Exposure duration
60 minutes of FK866 exposure after 30-minute oxidative pretreatment.
Method
Cells pretreated with 200 μM H2O2 or water vehicle for 30 minutes; medium replaced before the 60-minute recovery phase.
Vehicle
Pretreatment vehicle: ddH2O. Recovery-phase control: medium vehicle; FK866 stock solvent is DMSO, but final culture solvent concentration is not specified in the read assay method.
Co-treatment
FK866 co-administered with P7C3-A20 3 μM or nicotinamide 1 mM during recovery. P7C3-A20 concentration-response (0.03–3 μM), oxidative control and unstressed controls provide context within this design.
Reported limits
Final FK866 culture vehicle concentration not specified in the read assay method. Endpoint does not distinguish NAD+ from NADH.
Methods and source locations

Compound reported in the paper: FK866; Compound label in the paper: FK866

Compound-level research findings; no validation of A11279 purity, lot, salt equivalence or performance.

Results s2-4; Figure 6A-C and caption; Methods s4-14 (In vitro NAD/NADH determination), s4-2 (FK866 identity) and s4-21 (Statistics)

Intracellular NAD/NADH recovery after oxidative depletion: NAD/NADH-Glo luminescence, normalized to vehicle-treated cells; 4–5 independent experiments, each condition in quadruplicate. Bars are mean ± SEM. Caption specifies one-way ANOVA with Dunnett’s post-hoc test; no precise effect size inferred from bars. — Figure 6A-C; Results s2-4; Methods s4-14

FK866 In Vivo Studies

In a rat paclitaxel-neuropathy study, FK866 blocked P7C3-A20-associated protection against mechanical allodynia and nerve-fiber loss. FK866 alone did not alter the selected endpoints, and its combination with paclitaxel did not exacerbate those endpoints. These findings describe a pharmacological antagonist experiment. [2]

FK866 antagonizes P7C3-A20-associated neuroprotection in rats

Animal study · Adult male Sprague-Dawley rats in a paclitaxel peripheral-neuropathy model [2]

FK866 was used as a pharmacological antagonist: it blocked P7C3-A20-associated protection against paclitaxel neuropathy. FK866 alone did not alter the selected behavioral/histologic endpoints and did not exacerbate these endpoints with paclitaxel.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical allodynia (paw-withdrawal-threshold AUC) and intraepidermal nerve-fiber densityQualitative antagonist effect P7C3-A20 protection was blocked by FK866; FK866-alone and FK866+paclitaxel negative controls retained.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Twice daily; second injection 6 hours after the first (1.0 mg/kg/day total as reported).
Treatment course
Started on day −2 and continued until sacrifice; precise terminal day unresolved between main caption and supplement diagram.
Vehicle
DMSO/Kolliphor/PBS, 1:4:10.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
FK866 alone
FK866 0.5 mg/kg per injection. Other treatments: P7C3-A20 vehicle and paclitaxel vehicle.
Matched vehicle groups with the corresponding paclitaxel and P7C3-A20 assignments; see Figure 5B-C and supplement 1.Authors report no alteration of body weight, mechanical sensitivity or intraepidermal nerve-fiber density.[2]
FK866 with paclitaxel
FK866 0.5 mg/kg per injection. Paclitaxel 11.7 mg/kg i.p. on days 0, 2 and 4 (reported cumulative 35 mg/kg); P7C3-A20 vehicle.
Matched vehicle groups with the corresponding paclitaxel and P7C3-A20 assignments; see Figure 5B-C and supplement 1.Authors report that FK866 did not exacerbate paclitaxel-induced mechanical allodynia or intraepidermal nerve-fiber loss.[2]
FK866 with P7C3-A20 and paclitaxel
FK866 0.5 mg/kg per injection. P7C3-A20 10 mg/kg/day i.p.; paclitaxel 11.7 mg/kg i.p. on days 0, 2 and 4 (reported cumulative 35 mg/kg).
Matched vehicle groups with the corresponding paclitaxel and P7C3-A20 assignments; see Figure 5B-C and supplement 1.FK866 blocked P7C3-A20-associated protection against paclitaxel-induced mechanical allodynia and intraepidermal nerve-fiber degeneration.[2]
FK866 alone
Model: Adult male Sprague-Dawley rats (250–300 g at study entry)
Reported limits: Main caption identifies tissue collection as day 12; supplement diagram identifies day 10. Exact terminal course remains unresolved. No digitized effect size adopted.
FK866 with paclitaxel
Model: Adult male Sprague-Dawley rats (250–300 g at study entry)
Reported limits: Main caption identifies tissue collection as day 12; supplement diagram identifies day 10. Exact terminal course remains unresolved. No digitized effect size adopted.
FK866 with P7C3-A20 and paclitaxel
Model: Adult male Sprague-Dawley rats (250–300 g at study entry)
Reported limits: Main caption identifies tissue collection as day 12; supplement diagram identifies day 10. Exact terminal course remains unresolved. No digitized effect size adopted.
Methods and source locations

Compound reported in the paper: FK866; Compound label in the paper: FK866

Compound-level research findings; no validation of A11279 purity, lot, salt equivalence or performance.

Results s2-3; Figure 5A-C and caption; Figure 5—figure supplement 1A-C; Methods s4-1, s4-2, s4-5, s4-8 to s4-10, s4-21

Mechanical allodynia (paw-withdrawal-threshold AUC) and intraepidermal nerve-fiber density: Electronic von Frey testing and PGP9.5/collagen-IV-based nerve-fiber counting. Figure 5B-C caption: n = 4–6 rats/group, mean ± SEM, one-way ANOVA with Sidak’s post-hoc test. Supplement 1 time courses: n = 5–8 rats/group. Individual rats, not fields/sections, are experimental units; no exact numeric effect size extracted. The caption n range is reported rather than independently reconciled for the separated gray reference group. — Figure 5B-C and caption; Results s2-3; supplement 1B-C

FK866 alone · Results s2-3; Figure 5A-C and caption; Figure 5—figure supplement 1A-C; Methods s4-1, s4-2, s4-5, s4-8 to s4-10, s4-21

FK866 with paclitaxel · Results s2-3; Figure 5A-C and caption; Figure 5—figure supplement 1A-C; Methods s4-1, s4-2, s4-5, s4-8 to s4-10, s4-21

FK866 with P7C3-A20 and paclitaxel · Results s2-3; Figure 5A-C and caption; Figure 5—figure supplement 1A-C; Methods s4-1, s4-2, s4-5, s4-8 to s4-10, s4-21

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 658084-64-1
Applications NMPRTase Inhibitor
Formula C24H29N3O2
Molecular Weight 391.5
Synonyms K 22.175
SMILES
C1CN(CCC1CCCCNC(=O)/C=C/C2=CN=CC=C2)C(=O)C3=CC=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Insoluble
Ethanol 77 mg/mL (196.67 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
3 mg/mL
Vehicle
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

FK866 Research References

  1. [1] Burgos ES, Schramm VL. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry (2008). PMID: 18823127 DOI: 10.1021/bi801198m Source material
  2. [2] LoCoco PM, Risinger AL, Smith HR, et al. Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. eLife (2017). PMID: 29125463 DOI: 10.7554/elife.29626 Source material

Publications

7 publications citing this product

  1. Natsuko Kitajima, .et al. , J Cell Mol Med, 2026, May 20;30(10):e71187 PMID: 42159653
  2. T Nakajo, .et al. , Biochem Biophys Res Commun, 2024, Oct 30:731:150371 PMID: 39004065
  3. Takeshi Katayoshi, .et al. , Sci Rep, 2022, Nov 9;12(1):19040 PMID: 36352014
  4. Takeshi Nakamura, .et al. , Shimane Journal of Medical Science, 2022, 38 (2), 59-66
  5. Takeshi Katayoshi, .et al. , J Photochem Photobiol B, 2021, Jun 12;221:112238 PMID: 34130091
  6. Yool Lee, .et al. , Sci Adv, 2021, 7 PMID: 33579708
  7. Peter M LoCoco, .et al. , eLife, 2017, 6: e29626 PMID: 29125463

Added to your cart

View Cart Checkout
Loading...